Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

N. Sunaga, K. Kaira, H. Imai, K. Shimizu, T. Nakano, D. S. Shames, L. Girard, J. Soh, M. Sato, Y. Iwasaki, T. Ishizuka, A. F. Gazdar, J. D. Minna, M. Mori